Investors

Why BioVaxys

BioVaxys was founded in 2018 to improve on protein haptenization and leverage previous vaccine development efforts by Dr David Berd while at Thomas Jefferson University and with the former Avax Technologies, Inc.

Haptenized Antigen Platform:

• Over $100M in prior R&D investment by Avax
• Proven technology
• MVax® / OVax®  (for melanoma & ovarian cancer) was entering Ph III
• Phase I/II data in ovarian cancer & melanoma, safety, dose-ranging data
• Established clinical study design, manufacturing & distribution protocols

Value-Added Technology Enhancements By Biovaxys

• Proprietary enhancements by BioVaxys including  bi-haptenization and combined use of our vaccine with anti-CTLA4 and anti-PDA checkpoint antibodies
• Antiviral vaccine technology platform